Capmatinib is an orally bioavailable inhibitor of the proto-oncogene c-Met (also known as hepatocyte growth factor receptor (HGFR)) with potential antineoplastic activity. Capmatinib selectively binds to c-Met, thereby inhibiting c-Met phosphorylation and disrupting c-Met signal transduction pathways. This may induce cell death in tumor cells by overexpressing the c-Met protein or expressing the constitutively activated c-Met protein. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis.
Capmatinib is a small molecule kinase inhibitor targeted against c-Met (a.k.a. hepatocyte growth factor receptor [HGFR]), a receptor tyrosine kinase that, in healthy humans, activates signaling cascades involved in organ regeneration and tissue repair. Aberrant c-Met activation – via mutations, amplification, and/or overexpression – is known to occur in many types of cancer and leads to the overactivation of multiple downstream signaling pathways such as STAT3, PI3K/ATK, and RAS/MAPK. Mutations in MET have been detected in non-small cell lung cancer (NSCLC), and the prevalence of MET amplification in epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI)-naive patients with NSCLC has been reported to be 1.4% – 21%. This co-occurrence has made c-Met a desirable target in the treatment of NSCLC. Manufactured by Novartis and marketed under the brand name Tabrecta, capmatinib was granted accelerated approval by the FDA on May 6, 2020, for the treatment of NSCLC in patients whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping. The presence of the mutation must be confirmed by an FDA-approved test, such as the FoundationOne CDx assay (manufactured by Foundation Medicine, Inc.), which was approved by the FDA on the same day. As this indication was granted under accelerated approval, its continued approval is contingent upon the verification of capmatinib’s benefit in confirmatory trials.
Capmatinib is a Kinase Inhibitor. The mechanism of action of capmatinib is as a Mesenchymal Epithelial Transition Inhibitor, Cytochrome P450 1A2 Inhibitor, and P-Glycoprotein Inhibitor, Breast Cancer Resistance Protein Inhibitor, Multidrug and Toxin Extrusion Transporter 1 Inhibitor, and Multidrug and Toxin Extrusion Transporter 2 K Inhibitor.
Capmatinib Hydrochloride is the hydrochloride salt form of capmatinib, an orally bioavailable inhibitor of the proto-oncogene c-Met (also known as hepatocyte growth factor receptor (HGFR)) with potential antineoplastic activity. Capmatinib selectively binds to c-Met, thereby inhibiting c-Met phosphorylation and disrupting c-Met signal transduction pathways. This may induce cell death in tumor cells by overexpressing the c-Met protein or expressing the constitutively activated c-Met protein. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis.
Mechanism of Action
Aberrant activation of c-Met has been documented in many cancers, including non-small cell lung cancer (NSCLC). Mutations that result in the skipping of _MET_ exon 14 lead to the formation of a mutant c-Met with a missing regulatory domain – these mutant proteins have a reduced ability to negatively regulate, leading to a pathological increase in their downstream activity. Capmatinib inhibits the phosphorylation of both wild-type and mutant variants of c-Met triggered by the binding of its endogenous ligand, hepatocyte growth factor – in doing so, it prevents c-Met-mediated phosphorylation of downstream signaling proteins, as well as the proliferation and survival of c-Met-dependent tumor cells.
Capmatinib inhibits the overactivity of c-Met, a receptor tyrosine kinase encoded by the _MET_ proto-oncogene. Mutations in _MET_ are involved in the proliferation of many cancers, including non-small cell lung cancer (NSCLC). Capmatinib may cause photosensitivity reactions in patients following ultraviolet (UV) exposure – patients undergoing therapy with capmatinib should be advised to use sunscreen and protective clothing to limit exposure to UV radiation. Instances of interstitial lung disease/pneumonitis, which can be fatal, occurred in patients being treated with capmatinib. Patients presenting with signs or symptoms of lung disease (e.g. cough, dyspnea, fever) should have capmatinib immediately withheld, and capmatinib should be permanently discontinued if no other feasible causes of the lung-related symptoms are identified.
Indications
- Capmatinib is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test.
- Tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harboring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (METex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.
- Capmatinib is a kinase inhibitor indicated for the treatment of adults with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test.
- In the US, capmatinib is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test.
- Capmatinib is approved to treat adults with locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC) with MET exon 14 skipping alterations in Canada.[rx]
- Metastatic Non-Small Cell Lung Cancer
- Unresectable, locally advanced Non-Small Cell Lung Carcinoma (NSCLC)
Use in Cancer
Capmatinib hydrochloride is approved to treat:
- Non-small cell lung cancer has a certain mutation in the MET gene. It is used in adults whose cancer has spread to other parts of the body.
Capmatinib hydrochloride is also being studied in the treatment of other types of cancer.
Contraindication
- abnormal liver function tests
- pregnancy
- a patient who is producing milk and breastfeeding
- lung tissue problem
- pancreatitis
Dosage
Strengths: 150 mg; 200 mg
Non-Small Cell Lung Cancer
- 400 mg orally 2 times daily
- For the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an approved test
Dose Adjustments
DOSE MODIFICATION RECOMMENDATIONS:
- First dose reduction: 300 mg orally 2 times daily
- Second dose reduction: 300 mg orally 2 times daily
- Permanently discontinue this drug in patients who are unable to tolerate 200 mg orally 2 times daily.
DOSE MODIFICATION FOR ADVERSE REACTIONS:
INTERSTITIAL LUNG DISEASE (ILD)/PNEUMONITIS:
- Any Grade: Permanently discontinue this drug.
Increased ALT and/or AST without increased total bilirubin:
- Grade 3: Withhold therapy until recovery to baseline ALT/AST; if recovered to baseline within 7 days, resume this drug at the same dose; otherwise resume at a reduced dose.
- Grade 4: Permanently discontinue this drug.
INCREASED ALT AND/OR AST WITH INCREASED TOTAL BILIRUBIN IN THE ABSENCE OF CHOLESTASIS OR HEMOLYSIS:
- ALT and/or AST greater than 3 times the upper limit of normal (ULN) with total bilirubin greater than 2 x ULN: Permanently discontinue this drug.
INCREASED TOTAL BILIRUBIN WITHOUT CONCURRENT INCREASED ALT AND/OR AST:
- Grade 2: Withhold therapy until recovery to baseline bilirubin; if recovered to baseline within 7 days, resume this drug at the same dose; otherwise resume at a reduced dose.
- Grade 3: Withhold therapy until recovery to baseline bilirubin; if recovered to baseline within 7 days, resume this drug at a reduced dose; otherwise permanently discontinue this drug.
- Grade 4: Permanently discontinue this drug.
OTHER ADVERSE REACTIONS:
- Grade 2: Maintain dose level; if intolerable, consider withholding this drug until resolved, then resume at a reduced dose.
- Grade 3: Withhold this drug until resolved then resume at a reduced dose.
- Grade 4: Permanently discontinue this drug.
Side Effects
The Most Common
- vomiting
- nausea
- diarrhea
- constipation
- muscle, bone, or back pain
- loss of appetite
- tiredness and weakness
- dizziness
- swelling in hands, feet, ankles, or lower legs
- rash
- shortness of breath or trouble breathing, cough, fever, or other signs of infection
- chest pain
- pain in right upper part of the stomach; swelling in your stomach area; unusual bruising or bleeding; dark urine; yellowing of the skin and eyes; nausea, vomiting; light-colored stools; loss of appetite
- ongoing pain that begins in the stomach area, but may spread to the back; nausea; vomiting; weight loss
More Common
- our skin or the white part of your eyes turns yellow
(jaundice) - loss of appetite for several days or longer
- dark or “tea-colored” urine o nausea and vomiting
- light-colored stools (bowel movements)
- confusion
- pain, aching, or tenderness on the right side of your
- stomach area (abdomen)
- tiredness o weakness
- swelling in your stomach-area
Rare
- new or worsening cough, chest pain, trouble breathing;
- fever, cough with mucus;
- severe ongoing nausea and vomiting; or
- signs of liver or pancreas problems–loss of appetite, upper stomach pain (that may spread to your back), nausea or vomiting, fast heart rate, dark urine, jaundice (yellowing of the skin or eyes).
- trouble breathing;
- vomiting decreased appetite;
- feeling weak or tired
- abnormal liver function tests;
- swelling in your hands or feet.
Drug Interaction
DRUG | INTERACTION |
---|---|
Abaloparatide | The therapeutic efficacy of Abaloparatide can be decreased when used in combination with Capmatinib. |
Abametapir | The serum concentration of Capmatinib can be increased when it is combined with Abametapir. |
Abemaciclib | The serum concentration of Abemaciclib can be increased when it is combined with Capmatinib. |
Acalabrutinib | The serum concentration of Capmatinib can be increased when it is combined with Acalabrutinib. |
Acenocoumarol | The serum concentration of Acenocoumarol can be increased when it is combined with Capmatinib. |
Acetaminophen | The serum concentration of Capmatinib can be decreased when it is combined with Acetaminophen. |
Acyclovir | The metabolism of Acyclovir can be decreased when combined with Capmatinib. |
Afatinib | The serum concentration of Afatinib can be increased when it is combined with Capmatinib. |
Agomelatine | The metabolism of Agomelatine can be decreased when combined with Capmatinib. |
Albendazole | The metabolism of Albendazole can be decreased when combined with Capmatinib. |
Allopurinol | The serum concentration of Allopurinol can be increased when it is combined with Capmatinib. |
Alosetron | The metabolism of Alosetron can be decreased when combined with Capmatinib. |
Alpelisib | The serum concentration of Capmatinib can be decreased when it is combined with Alpelisib. |
Ambrisentan | The serum concentration of Ambrisentan can be increased when it is combined with Capmatinib. |
Aminoglutethimide | The serum concentration of Capmatinib can be decreased when it is combined with Aminoglutethimide. |
Aminophenazone | The metabolism of Aminophenazone can be decreased when combined with Capmatinib. |
Aminophylline | The serum concentration of Aminophylline can be increased when it is combined with Capmatinib. |
Amiodarone | The serum concentration of Capmatinib can be increased when it is combined with Amiodarone. |
Amitriptyline | The metabolism of Amitriptyline can be decreased when combined with Capmatinib. |
Amobarbital | The serum concentration of Capmatinib can be decreased when it is combined with Amobarbital. |
Amprenavir | The metabolism of Capmatinib can be decreased when combined with Amprenavir. |
Anagrelide | The serum concentration of Anagrelide can be increased when it is combined with Capmatinib. |
Antipyrine | The metabolism of Antipyrine can be decreased when combined with Capmatinib. |
Apalutamide | The serum concentration of Capmatinib can be decreased when it is combined with Apalutamide. |
Apixaban | The serum concentration of Apixaban can be increased when it is combined with Capmatinib. |
Apremilast | The metabolism of Apremilast can be decreased when combined with Capmatinib. |
Aprepitant | The metabolism of Capmatinib can be decreased when combined with Aprepitant. |
Armodafinil | The serum concentration of Capmatinib can be decreased when it is combined with Armodafinil. |
Artemether | The serum concentration of Capmatinib can be decreased when it is combined with Artemether. |
Articaine | The risk or severity of methemoglobinemia can be increased when Capmatinib is combined with Articaine. |
Asenapine | The metabolism of Asenapine can be decreased when combined with Capmatinib. |
Asunaprevir | The serum concentration of Capmatinib can be decreased when it is combined with Asunaprevir. |
Atazanavir | The serum concentration of Capmatinib can be increased when it is combined with Atazanavir. |
Avanafil | The serum concentration of Avanafil can be increased when it is combined with Capmatinib. |
Avatrombopag | The serum concentration of Avatrombopag can be increased when it is combined with Capmatinib. |
Axitinib | The serum concentration of Axitinib can be increased when it is combined with Capmatinib. |
Azatadine | The serum concentration of Capmatinib can be decreased when it is combined with Azatadine. |
Azathioprine | The metabolism of Azathioprine can be decreased when combined with Capmatinib. |
Azelastine | The metabolism of Azelastine can be decreased when combined with Capmatinib. |
Baricitinib | The excretion of Baricitinib can be decreased when combined with Capmatinib. |
Beclomethasone | The serum concentration of Capmatinib can be decreased when it is combined with Beclomethasone dipropionate. |
Belantamab mafodotin | The serum concentration of Belantamab mafodotin can be increased when it is combined with Capmatinib. |
Belinostat | The serum concentration of Belinostat can be increased when it is combined with Capmatinib. |
Bendamustine | The serum concentration of Bendamustine can be increased when it is combined with Capmatinib. |
Benzocaine | The risk or severity of methemoglobinemia can be increased when Capmatinib is combined with Benzocaine. |
Benzyl alcohol | The risk or severity of methemoglobinemia can be increased when Capmatinib is combined with Benzyl alcohol. |
Berotralstat | The serum concentration of Berotralstat can be increased when it is combined with Capmatinib. |
Betamethasone | The serum concentration of Capmatinib can be decreased when it is combined with Betamethasone. |
Betaxolol | The metabolism of Betaxolol can be decreased when combined with Capmatinib. |
Betrixaban | The serum concentration of Betrixaban can be increased when it is combined with Capmatinib. |
Bexarotene | The serum concentration of Capmatinib can be decreased when it is combined with Bexarotene. |
Binimetinib | The serum concentration of Binimetinib can be increased when it is combined with Capmatinib. |
Bisoprolol | The serum concentration of Bisoprolol can be increased when it is combined with Capmatinib. |
Boceprevir | The metabolism of Capmatinib can be decreased when combined with Boceprevir. |
Bortezomib | The serum concentration of Bortezomib can be increased when it is combined with Capmatinib. |
Bosentan | The serum concentration of Capmatinib can be decreased when it is combined with Bosentan. |
Bosutinib | The serum concentration of Bosutinib can be increased when it is combined with Capmatinib. |
Brentuximab vedotin | The serum concentration of Brentuximab vedotin can be increased when it is combined with Capmatinib. |
Brigatinib | The serum concentration of Capmatinib can be decreased when it is combined with Brigatinib. |
Bromazepam | The metabolism of Bromazepam can be decreased when combined with Capmatinib. |
Bromotheophylline | The metabolism of Bromotheophylline can be decreased when combined with Capmatinib. |
Budesonide | The serum concentration of Capmatinib can be decreased when it is combined with Budesonide. |
Bupivacaine | The risk or severity of methemoglobinemia can be increased when Capmatinib is combined with Bupivacaine. |
Butacaine | The risk or severity of methemoglobinemia can be increased when Capmatinib is combined with Butacaine. |
Butalbital | The serum concentration of Capmatinib can be decreased when it is combined with Butalbital. |
Butamben | The risk or severity of methemoglobinemia can be increased when Capmatinib is combined with Butamben. |
Cabazitaxel | The serum concentration of Cabazitaxel can be increased when it is combined with Capmatinib. |
Cabergoline | The serum concentration of Cabergoline can be increased when it is combined with Capmatinib. |
Caffeine | The metabolism of Caffeine can be decreased when combined with Capmatinib. |
Calcitriol | The serum concentration of Capmatinib can be decreased when it is combined with Calcitriol. |
Canagliflozin | The serum concentration of Canagliflozin can be increased when it is combined with Capmatinib. |
Capsaicin | The risk or severity of methemoglobinemia can be increased when Capmatinib is combined with Capsaicin. |
Carbamazepine | The serum concentration of Capmatinib can be decreased when it is combined with Carbamazepine. |
Carbimazole | The therapeutic efficacy of Carbimazole can be decreased when used in combination with Capmatinib. |
Carfilzomib | The serum concentration of Carfilzomib can be increased when it is combined with Capmatinib. |
Carmustine | The metabolism of Carmustine can be decreased when combined with Capmatinib. |
Carvedilol | The metabolism of Carvedilol can be decreased when combined with Capmatinib. |
Cefradine | The serum concentration of Capmatinib can be decreased when it is combined with Cefradine. |
Celecoxib | The serum concentration of Celecoxib can be increased when it is combined with Capmatinib. |
Cenobamate | The serum concentration of Capmatinib can be decreased when it is combined with Cenobamate. |
Cephalexin | The excretion of Cephalexin can be decreased when combined with Capmatinib. |
Ceritinib | The serum concentration of Ceritinib can be increased when it is combined with Capmatinib. |
Cerivastatin | The serum concentration of Capmatinib can be decreased when it is combined with Cerivastatin. |
Chloroprocaine | The risk or severity of methemoglobinemia can be increased when Capmatinib is combined with Chloroprocaine. |
Chlorphenesin | The serum concentration of Capmatinib can be decreased when it is combined with Chlorphenesin. |
Chlorpromazine | The metabolism of Chlorpromazine can be decreased when combined with Capmatinib. |
Chlorzoxazone | The metabolism of Chlorzoxazone can be decreased when combined with Capmatinib. |
Cilostazol | The metabolism of Cilostazol can be decreased when combined with Capmatinib. |
Cimetidine | The serum concentration of Capmatinib can be increased when it is combined with Cimetidine. |
Cinacalcet | The metabolism of Cinacalcet can be decreased when combined with Capmatinib. |
Cinchocaine | The risk or severity of methemoglobinemia can be increased when Capmatinib is combined with Cinchocaine. |
Cinnarizine | The metabolism of Cinnarizine can be decreased when combined with Capmatinib. |
Ciprofloxacin | The serum concentration of Capmatinib can be increased when it is combined with Ciprofloxacin. |
Cladribine | The serum concentration of Cladribine can be increased when it is combined with Capmatinib. |
Clarithromycin | The serum concentration of Capmatinib can be increased when it is combined with Clarithromycin. |
Clevidipine | The serum concentration of Capmatinib can be decreased when it is combined with Clevidipine. |
Clobazam | The serum concentration of Capmatinib can be decreased when it is combined with Clobazam. |
Clofarabine | The serum concentration of Clofarabine can be increased when it is combined with Capmatinib. |
Clofazimine | The serum concentration of Capmatinib can be increased when it is combined with Clofazimine. |
Clofibrate | The serum concentration of Capmatinib can be decreased when it is combined with Clofibrate. |
Clomifene | The serum concentration of Clomifene can be increased when it is combined with Capmatinib. |
Clomipramine | The serum concentration of Clomipramine can be increased when it is combined with Capmatinib. |
Clonidine | The serum concentration of Clonidine can be increased when it is combined with Capmatinib. |
Clopidogrel | The metabolism of Clopidogrel can be decreased when combined with Capmatinib. |
Clotrimazole | The serum concentration of Capmatinib can be decreased when it is combined with Clotrimazole. |
Clozapine | The serum concentration of Capmatinib can be decreased when it is combined with Clozapine. |
Cobicistat | The serum concentration of Capmatinib can be increased when it is combined with Cobicistat. |
Cobimetinib | The serum concentration of Cobimetinib can be increased when it is combined with Capmatinib. |
Cocaine | The risk or severity of methemoglobinemia can be increased when Capmatinib is combined with Cocaine. |
Colchicine | The serum concentration of Colchicine can be increased when it is combined with Capmatinib. |
Conivaptan | The metabolism of Capmatinib can be decreased when combined with Conivaptan. |
Conjugated estrogens | The serum concentration of Conjugated estrogens can be increased when it is combined with Capmatinib. |
Copanlisib | The serum concentration of Copanlisib can be increased when it is combined with Capmatinib. |
Corticotropin | The serum concentration of Capmatinib can be decreased when it is combined with Corticotropin. |
Crizotinib | The serum concentration of Capmatinib can be increased when it is combined with Crizotinib. |
Curcumin | The metabolism of Capmatinib can be decreased when combined with Curcumin. |
Cyclobenzaprine | The metabolism of Cyclobenzaprine can be decreased when combined with Capmatinib. |
Cyclophosphamide | The serum concentration of Capmatinib can be decreased when it is combined with Cyclophosphamide. |
Cyclosporine | The serum concentration of Cyclosporine can be increased when it is combined with Capmatinib. |
Dabigatran etexilate | The serum concentration of Dabigatran etexilate can be increased when it is combined with Capmatinib. |
Dabrafenib | The serum concentration of Capmatinib can be decreased when it is combined with Dabrafenib. |
Dacarbazine | The serum concentration of Dacarbazine can be increased when it is combined with Capmatinib. |
Dacomitinib | The serum concentration of Dacomitinib can be increased when it is combined with Capmatinib. |
Dactinomycin | The serum concentration of Dactinomycin can be increased when it is combined with Capmatinib. |
Danazol | The metabolism of Capmatinib can be decreased when combined with Danazol. |
Dapagliflozin | The metabolism of Dapagliflozin can be decreased when combined with Capmatinib. |
Daptomycin | The serum concentration of Daptomycin can be increased when it is combined with Capmatinib. |
Darbepoetin alfa | The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Capmatinib. |
Darolutamide | The serum concentration of Darolutamide can be increased when it is combined with Capmatinib. |
Darunavir | The metabolism of Capmatinib can be decreased when combined with Darunavir. |
Dasabuvir | The serum concentration of Dasabuvir can be increased when it is combined with Capmatinib. |
Dasatinib | The serum concentration of Dasatinib can be increased when it is combined with Capmatinib. |
Daunorubicin | The serum concentration of Capmatinib can be decreased when it is combined with Daunorubicin. |
Deferasirox | The serum concentration of Capmatinib can be decreased when it is combined with Deferasirox. |
Delafloxacin | The serum concentration of Capmatinib can be decreased when it is combined with Delafloxacin. |
Delavirdine | The metabolism of Capmatinib can be decreased when combined with Delavirdine. |
Desonide | The serum concentration of Capmatinib can be decreased when it is combined with Desonide. |
Desvenlafaxine | The metabolism of Capmatinib can be decreased when combined with Desvenlafaxine. |
Dexamethasone | The serum concentration of Capmatinib can be decreased when it is combined with Dexamethasone. |
Dexamethasone acetate | The serum concentration of Capmatinib can be decreased when it is combined with Dexamethasone acetate. |
Dexfenfluramine | The metabolism of Dexfenfluramine can be decreased when combined with Capmatinib. |
Diclofenac | The metabolism of Diclofenac can be decreased when combined with Capmatinib. |
Dicloxacillin | The serum concentration of Capmatinib can be decreased when it is combined with Dicloxacillin. |
Digitoxin | The serum concentration of Digitoxin can be increased when it is combined with Capmatinib. |
Digoxin | The serum concentration of Digoxin can be increased when it is combined with Capmatinib. |
Dihydralazine | The metabolism of Dihydralazine can be decreased when combined with Capmatinib. |
Diltiazem | The serum concentration of Capmatinib can be increased when it is combined with Diltiazem. |
Diphenhydramine | The risk or severity of methemoglobinemia can be increased when Capmatinib is combined with Diphenhydramine. |
Disopyramide | The metabolism of Disopyramide can be decreased when combined with Capmatinib. |
Dolutegravir | The serum concentration of Dolutegravir can be increased when it is combined with Capmatinib. |
Domperidone | The metabolism of Domperidone can be decreased when combined with Capmatinib. |
Donepezil | The serum concentration of Donepezil can be increased when it is combined with Capmatinib. |
Doxepin | The metabolism of Doxepin can be decreased when combined with Capmatinib. |
Doxorubicin | The serum concentration of Doxorubicin can be increased when it is combined with Capmatinib. |
Dronedarone | The metabolism of Capmatinib can be decreased when combined with Dronedarone. |
Duvelisib | The serum concentration of Duvelisib can be increased when it is combined with Capmatinib. |
Dyclonine | The risk or severity of methemoglobinemia can be increased when Capmatinib is combined with Dyclonine. |
Edoxaban | The serum concentration of Edoxaban can be increased when it is combined with Capmatinib. |
Efavirenz | The serum concentration of Capmatinib can be decreased when it is combined with Efavirenz. |
Elagolix | The serum concentration of Capmatinib can be decreased when it is combined with Elagolix. |
Elbasvir | The serum concentration of Elbasvir can be increased when it is combined with Capmatinib. |
Eletriptan | The serum concentration of Capmatinib can be decreased when it is combined with Eletriptan. |
Eltrombopag | The metabolism of Eltrombopag can be decreased when combined with Capmatinib. |
Elvitegravir | The metabolism of Capmatinib can be decreased when combined with Elvitegravir. |
Emtricitabine | The excretion of Emtricitabine can be decreased when combined with Capmatinib. |
Enasidenib | The serum concentration of Capmatinib can be decreased when it is combined with Enasidenib. |
Enfortumab vedotin | The serum concentration of Enfortumab vedotin can be increased when it is combined with Capmatinib. |
Entecavir | The metabolism of Entecavir can be decreased when combined with Capmatinib. |
Enzalutamide | The serum concentration of Capmatinib can be decreased when it is combined with Enzalutamide. |
Ergotamine | The metabolism of Capmatinib can be decreased when combined with Ergotamine. |
Erlotinib | The serum concentration of Erlotinib can be increased when it is combined with Capmatinib. |
Ertugliflozin | The serum concentration of Ertugliflozin can be increased when it is combined with Capmatinib. |
Erythromycin | The serum concentration of Capmatinib can be increased when it is combined with Erythromycin. |
Erythropoietin | The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Capmatinib. |
Esketamine | The serum concentration of Capmatinib can be decreased when it is combined with Esketamine. |
Eslicarbazepine | The serum concentration of Capmatinib can be decreased when it is combined with Eslicarbazepine. |
Eslicarbazepine acetate | The serum concentration of Capmatinib can be decreased when it is combined with Eslicarbazepine acetate. |
Estradiol | The metabolism of Estradiol can be decreased when combined with Capmatinib. |
Estradiol acetate | The serum concentration of Capmatinib can be decreased when it is combined with Estradiol acetate. |
Estradiol benzoate | The serum concentration of Capmatinib can be decreased when it is combined with Estradiol benzoate. |
Estradiol cypionate | The serum concentration of Capmatinib can be decreased when it is combined with Estradiol cypionate. |
Estradiol dienanthate | The serum concentration of Capmatinib can be decreased when it is combined with Estradiol dienanthate. |
Estradiol valerate | The serum concentration of Capmatinib can be decreased when it is combined with Estradiol valerate. |
Estrone sulfate | The metabolism of Estrone sulfate can be decreased when combined with Capmatinib. |
Ethanol | The serum concentration of Capmatinib can be decreased when it is combined with Ethanol. |
Ethinylestradiol | The metabolism of Ethinylestradiol can be decreased when combined with Capmatinib. |
Ethotoin | The serum concentration of Capmatinib can be decreased when it is combined with Ethotoin. |
Ethyl chloride | The risk or severity of methemoglobinemia can be increased when Capmatinib is combined with Ethyl chloride. |
Etidocaine | The risk or severity of methemoglobinemia can be increased when Capmatinib is combined with Etidocaine. |
Etoposide | The serum concentration of Capmatinib can be decreased when it is combined with Etoposide. |
Etoricoxib | The metabolism of Etoricoxib can be decreased when combined with Capmatinib. |
Etravirine | The serum concentration of Capmatinib can be decreased when it is combined with Etravirine. |
Everolimus | The serum concentration of Everolimus can be increased when it is combined with Capmatinib. |
Ezetimibe | The serum concentration of Ezetimibe can be increased when it is combined with Capmatinib. |
Fedratinib | The serum concentration of Fedratinib can be increased when it is combined with Capmatinib. |
Felbamate | The serum concentration of Capmatinib can be decreased when it is combined with Felbamate. |
Fenfluramine | The metabolism of Fenfluramine can be decreased when combined with Capmatinib. |
Fexinidazole | The serum concentration of Capmatinib can be increased when it is combined with Fexinidazole. |
Fexofenadine | The serum concentration of Fexofenadine can be increased when it is combined with Capmatinib. |
Flecainide | The metabolism of Flecainide can be decreased when combined with Capmatinib. |
Flucloxacillin | The serum concentration of Capmatinib can be decreased when it is combined with Flucloxacillin. |
Fluconazole | The metabolism of Capmatinib can be decreased when combined with Fluconazole. |
Flunarizine | The metabolism of Flunarizine can be decreased when combined with Capmatinib. |
Fluocinolone acetonide | The serum concentration of Capmatinib can be decreased when it is combined with Fluocinolone acetonide. |
Fluorouracil | The serum concentration of Fluorouracil can be increased when it is combined with Capmatinib. |
Fluoxetine | The metabolism of Fluoxetine can be decreased when combined with Capmatinib. |
Flutamide | The metabolism of Flutamide can be decreased when combined with Capmatinib. |
Fluvoxamine | The serum concentration of Capmatinib can be increased when it is combined with Fluvoxamine. |
Folic acid | The serum concentration of Folic acid can be increased when it is combined with Capmatinib. |
Follitropin | The therapeutic efficacy of Follitropin can be decreased when used in combination with Capmatinib. |
Formestane | The serum concentration of Capmatinib can be decreased when it is combined with Formestane. |
Fosaprepitant | The serum concentration of Capmatinib can be decreased when it is combined with Fosaprepitant. |
Fosnetupitant | The metabolism of Capmatinib can be decreased when combined with Fosnetupitant. |
Fosphenytoin | The serum concentration of Capmatinib can be decreased when it is combined with Fosphenytoin. |
Fostemsavir | The serum concentration of Fostemsavir can be increased when it is combined with Capmatinib. |
Frovatriptan | The metabolism of Frovatriptan can be decreased when combined with Capmatinib. |
Fusidic acid | The metabolism of Capmatinib can be decreased when combined with Fusidic acid. |
Futibatinib | The serum concentration of Futibatinib can be increased when it is combined with Capmatinib. |
Ganciclovir | The excretion of Ganciclovir can be decreased when combined with Capmatinib. |
Gefitinib | The serum concentration of Gefitinib can be increased when it is combined with Capmatinib. |
Gemcitabine | The serum concentration of Gemcitabine can be increased when it is combined with Capmatinib. |
Gilteritinib | The serum concentration of Gilteritinib can be increased when it is combined with Capmatinib. |
Glasdegib | The serum concentration of Glasdegib can be increased when it is combined with Capmatinib. |
Glecaprevir | The serum concentration of Capmatinib can be increased when it is combined with Glecaprevir. |
Glyburide | The serum concentration of Glyburide can be increased when it is combined with Capmatinib. |
Glycerol phenylbutyrate | The serum concentration of Capmatinib can be decreased when it is combined with Glycerol phenylbutyrate. |
Grapefruit | The serum concentration of Capmatinib can be increased when it is combined with Grapefruit. |
Grazoprevir | The serum concentration of Grazoprevir can be increased when it is combined with Capmatinib. |
Grepafloxacin | The metabolism of Grepafloxacin can be decreased when combined with Capmatinib. |
Griseofulvin | The serum concentration of Capmatinib can be decreased when it is combined with Griseofulvin. |
Guanabenz | The metabolism of Guanabenz can be decreased when combined with Capmatinib. |
Guanidine | The excretion of Guanidine can be decreased when combined with Capmatinib. |
Haloperidol | The serum concentration of Haloperidol can be increased when it is combined with Capmatinib. |
Hydrocortamate | The serum concentration of Capmatinib can be decreased when it is combined with Hydrocortamate. |
Hydrocortisone | The serum concentration of Capmatinib can be decreased when it is combined with Hydrocortisone. |
Hydrocortisone acetate | The serum concentration of Capmatinib can be decreased when it is combined with Hydrocortisone acetate. |
Hydrocortisone butyrate | The serum concentration of Capmatinib can be decreased when it is combined with Hydrocortisone butyrate. |
Hydrocortisone probutate | The serum concentration of Capmatinib can be decreased when it is combined with Hydrocortisone probutate. |
Hydrocortisone succinate | The serum concentration of Capmatinib can be decreased when it is combined with Hydrocortisone succinate. |
Hydrocortisone valerate | The serum concentration of Capmatinib can be decreased when it is combined with Hydrocortisone valerate. |
Idelalisib | The serum concentration of Capmatinib can be increased when it is combined with Idelalisib. |
Ifosfamide | The serum concentration of Capmatinib can be decreased when it is combined with Ifosfamide. |
Imatinib | The serum concentration of Imatinib can be increased when it is combined with Capmatinib. |
Imipramine | The serum concentration of Imipramine can be increased when it is combined with Capmatinib. |
Indacaterol | The serum concentration of Indacaterol can be increased when it is combined with Capmatinib. |
Indinavir | The serum concentration of Capmatinib can be increased when it is combined with Indinavir. |
Inotuzumab ozogamicin | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Capmatinib. |
Irinotecan | The serum concentration of Irinotecan can be increased when it is combined with Capmatinib. |
Isavuconazole | The serum concentration of Capmatinib can be decreased when it is combined with Isavuconazole. |
Isavuconazonium | The serum concentration of Capmatinib can be decreased when it is combined with Isavuconazonium. |
Isoniazid | The metabolism of Capmatinib can be decreased when combined with Isoniazid. |
Isradipine | The metabolism of Capmatinib can be decreased when combined with Isradipine. |
Istradefylline | The metabolism of Istradefylline can be decreased when combined with Capmatinib. |
Itraconazole | The serum concentration of Capmatinib can be increased when it is combined with Itraconazole. |
Ivermectin | The serum concentration of Ivermectin can be increased when it is combined with Capmatinib. |
Ivosidenib | The serum concentration of Capmatinib can be decreased when it is combined with Ivosidenib. |
Ketamine | The serum concentration of Capmatinib can be decreased when it is combined with Ketamine. |
Ketoconazole | The serum concentration of Capmatinib can be increased when it is combined with Ketoconazole. |
Lamivudine | The serum concentration of Lamivudine can be increased when it is combined with Capmatinib. |
Lansoprazole | The serum concentration of Capmatinib can be decreased when it is combined with Lansoprazole. |
Larotrectinib | The serum concentration of Larotrectinib can be increased when it is combined with Capmatinib. |
Lasmiditan | The serum concentration of Lasmiditan can be increased when it is combined with Capmatinib. |
Ledipasvir | The serum concentration of Ledipasvir can be increased when it is combined with Capmatinib. |
Lefamulin | Capmatinib may decrease the excretion rate of Lefamulin which could result in a higher serum level. |
Leflunomide | The serum concentration of Leflunomide can be increased when it is combined with Capmatinib. |
Lemborexant | The serum concentration of Lemborexant can be increased when it is combined with Capmatinib. |
Lenvatinib | The serum concentration of Lenvatinib can be increased when it is combined with Capmatinib. |
Lesinurad | The serum concentration of Capmatinib can be decreased when it is combined with Lesinurad. |
Levobupivacaine | The risk or severity of methemoglobinemia can be increased when Capmatinib is combined with Levobupivacaine. |
Levofloxacin | The excretion of Levofloxacin can be decreased when combined with Capmatinib. |
Levoketoconazole | The serum concentration of Capmatinib can be increased when it is combined with Levoketoconazole. |
Levothyroxine | The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Capmatinib. |
Lidocaine | The risk or severity of methemoglobinemia can be increased when Capmatinib is combined with Lidocaine. |
Linagliptin | The metabolism of Capmatinib can be decreased when combined with Linagliptin. |
Liothyronine | The therapeutic efficacy of Liothyronine can be decreased when used in combination with Capmatinib. |
Liotrix | The therapeutic efficacy of Liotrix can be decreased when used in combination with Capmatinib. |
Lofexidine | The metabolism of Lofexidine can be decreased when combined with Capmatinib. |
Lomefloxacin | The metabolism of Lomefloxacin can be decreased when combined with Capmatinib. |
Lonafarnib | The metabolism of Capmatinib can be decreased when combined with Lonafarnib. |
Loncastuximab tesirine | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Capmatinib. |
Loperamide | The excretion of Loperamide can be decreased when combined with Capmatinib. |
Lopinavir | The serum concentration of Capmatinib can be increased when it is combined with Lopinavir. |
Lorcaserin | The metabolism of Lorcaserin can be decreased when combined with Capmatinib. |
Lorlatinib | The serum concentration of Capmatinib can be decreased when it is combined with Lorlatinib. |
Lovastatin | The metabolism of Capmatinib can be decreased when combined with Lovastatin. |
Lumacaftor | The serum concentration of Capmatinib can be decreased when it is combined with Lumacaftor. |
Lusutrombopag | The serum concentration of Lusutrombopag can be increased when it is combined with Capmatinib. |
Mannitol | The serum concentration of Mannitol can be increased when it is combined with Capmatinib. |
Maprotiline | The metabolism of Maprotiline can be decreased when combined with Capmatinib. |
Mavacamten | The serum concentration of Capmatinib can be decreased when it is combined with Mavacamten. |
Medroxyprogesterone | The serum concentration of Capmatinib can be decreased when it is combined with Medroxyprogesterone acetate. |
Mefenamic acid | The metabolism of Mefenamic acid can be decreased when combined with Capmatinib. |
Mefloquine | The serum concentration of Mefloquine can be increased when it is combined with Capmatinib. |
Melatonin | The metabolism of Melatonin can be decreased when combined with Capmatinib. |
Meloxicam | The risk or severity of methemoglobinemia can be increased when Capmatinib is combined with Meloxicam. |
Mephenytoin | The metabolism of Mephenytoin can be decreased when combined with Capmatinib. |
Mepivacaine | The risk or severity of methemoglobinemia can be increased when Capmatinib is combined with Mepivacaine. |
Metformin | The excretion of Metformin can be decreased when combined with Capmatinib. |
Methadone | The serum concentration of Capmatinib can be increased when it is combined with Methadone. |
Methimazole | The metabolism of Capmatinib can be decreased when combined with Methimazole. |
Methylprednisolone | The serum concentration of Capmatinib can be decreased when it is combined with Methylprednisolone. |
Metoclopramide | The metabolism of Metoclopramide can be decreased when combined with Capmatinib. |
Metreleptin | The metabolism of Capmatinib can be increased when combined with Metreleptin. |
Metyrapone | The serum concentration of Capmatinib can be decreased when it is combined with Metyrapone. |
Mexiletine | The metabolism of Mexiletine can be decreased when combined with Capmatinib. |
Mianserin | The metabolism of Mianserin can be decreased when combined with Capmatinib. |
Miconazole | The metabolism of Capmatinib can be decreased when combined with Miconazole. |
Midostaurin | The serum concentration of Capmatinib can be decreased when it is combined with Midostaurin. |
Mifepristone | The serum concentration of Capmatinib can be decreased when it is combined with Mifepristone. |
Milnacipran | The metabolism of Capmatinib can be decreased when combined with Milnacipran. |
Mirabegron | The serum concentration of Mirabegron can be increased when it is combined with Capmatinib. |
Mirtazapine | The metabolism of Mirtazapine can be decreased when combined with Capmatinib. |
Mitotane | The serum concentration of Capmatinib can be decreased when it is combined with Mitotane. |
Mitoxantrone | The serum concentration of Mitoxantrone can be increased when it is combined with Capmatinib. |
Modafinil | The serum concentration of Capmatinib can be decreased when it is combined with Modafinil. |
Morphine | The serum concentration of Morphine can be increased when it is combined with Capmatinib. |
Mycophenolate mofetil | The serum concentration of Mycophenolate mofetil can be increased when it is combined with Capmatinib. |
Nabumetone | The metabolism of Nabumetone can be decreased when combined with Capmatinib. |
Nadolol | The excretion of Nadolol can be decreased when combined with Capmatinib. |
Nafcillin | The serum concentration of Capmatinib can be decreased when it is combined with Nafcillin. |
Naloxegol | The serum concentration of Naloxegol can be increased when it is combined with Capmatinib. |
Naloxone | The metabolism of Capmatinib can be decreased when combined with Naloxone. |
Naproxen | The metabolism of Naproxen can be decreased when combined with Capmatinib. |
Nefazodone | The serum concentration of Capmatinib can be increased when it is combined with Nefazodone. |
Nelfinavir | The serum concentration of Capmatinib can be increased when it is combined with Nelfinavir. |
Netupitant | The metabolism of Capmatinib can be decreased when combined with Netupitant. |
Nicardipine | The serum concentration of Capmatinib can be increased when it is combined with Nicardipine. |
Nifedipine | The serum concentration of Capmatinib can be decreased when it is combined with Nifedipine. |
Nilotinib | The serum concentration of Nilotinib can be increased when it is combined with Capmatinib. |
Nilvadipine | The metabolism of Capmatinib can be decreased when combined with Nilvadipine. |
Nintedanib | The serum concentration of Nintedanib can be increased when it is combined with Capmatinib. |
Nitrofurantoin | The serum concentration of Nitrofurantoin can be increased when it is combined with Capmatinib. |
Norgestimate | The serum concentration of Capmatinib can be decreased when it is combined with Norgestimate. |
Nortriptyline | The serum concentration of Nortriptyline can be increased when it is combined with Capmatinib. |
Olanzapine | The metabolism of Olanzapine can be decreased when combined with Capmatinib. |
Omadacycline | The serum concentration of Omadacycline can be increased when it is combined with Capmatinib. |
Ombitasvir | The serum concentration of Ombitasvir can be increased when it is combined with Capmatinib. |
Omeprazole | The serum concentration of Capmatinib can be decreased when it is combined with Omeprazole. |
Ondansetron | The metabolism of Ondansetron can be decreased when combined with Capmatinib. |
Oritavancin | The serum concentration of Capmatinib can be decreased when it is combined with Oritavancin. |
Osilodrostat | The serum concentration of Capmatinib can be increased when it is combined with Osilodrostat. |
Osimertinib | The serum concentration of Osimertinib can be increased when it is combined with Capmatinib. |
Oxaliplatin | The serum concentration of Oxaliplatin can be increased when it is combined with Capmatinib. |
Oxcarbazepine | The serum concentration of Capmatinib can be decreased when it is combined with Oxcarbazepine. |
Oxetacaine | The risk or severity of methemoglobinemia can be increased when Capmatinib is combined with Oxetacaine. |
Oxiconazole | The serum concentration of Capmatinib can be decreased when it is combined with Oxiconazole. |
Oxtriphylline | The metabolism of Oxtriphylline can be decreased when combined with Capmatinib. |
Oxybuprocaine | The risk or severity of methemoglobinemia can be increased when Capmatinib is combined with Oxybuprocaine. |
Ozanimod | Capmatinib may decrease the excretion rate of Ozanimod which could result in a higher serum level. |
Paclitaxel | The serum concentration of Capmatinib can be decreased when it is combined with Paclitaxel. |
Palbociclib | The serum concentration of Palbociclib can be increased when it is combined with Capmatinib. |
Paliperidone | The serum concentration of Paliperidone can be increased when it is combined with Capmatinib. |
Panobinostat | The serum concentration of Panobinostat can be increased when it is combined with Capmatinib. |
Parathyroid hormone | The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Capmatinib. |
Paritaprevir | The serum concentration of Paritaprevir can be increased when it is combined with Capmatinib. |
Paroxetine | The serum concentration of Capmatinib can be increased when it is combined with Paroxetine. |
Pazopanib | The serum concentration of Pazopanib can be increased when it is combined with Capmatinib. |
Peginesatide | The risk or severity of Thrombosis can be increased when Peginesatide is combined with Capmatinib. |
Pegvisomant | The serum concentration of Capmatinib can be decreased when it is combined with Pegvisomant. |
Pemetrexed | The metabolism of Pemetrexed can be decreased when combined with Capmatinib. |
Penciclovir | The metabolism of Penciclovir can be decreased when combined with Capmatinib. |
Pentobarbital | The serum concentration of Capmatinib can be decreased when it is combined with Pentobarbital. |
Pentoxifylline | The metabolism of Pentoxifylline can be decreased when combined with Capmatinib. |
Perampanel | The serum concentration of Capmatinib can be decreased when it is combined with Perampanel. |
Perphenazine | The metabolism of Perphenazine can be decreased when combined with Capmatinib. |
Phenobarbital | The serum concentration of Capmatinib can be decreased when it is combined with Phenobarbital. |
Phenol | The risk or severity of methemoglobinemia can be increased when Capmatinib is combined with Phenol. |
Phenylbutazone | The serum concentration of Capmatinib can be decreased when it is combined with Phenylbutazone. |
Phenytoin | The serum concentration of Capmatinib can be decreased when it is combined with Phenytoin. |
Pibrentasvir | The serum concentration of Pibrentasvir can be increased when it is combined with Capmatinib. |
Pimozide | The serum concentration of Pimozide can be increased when it is combined with Capmatinib. |
Pirfenidone | The metabolism of Pirfenidone can be decreased when combined with Capmatinib. |
Pitavastatin | The serum concentration of Pitavastatin can be increased when it is combined with Capmatinib. |
Pitolisant | The serum concentration of Capmatinib can be decreased when it is combined with Pitolisant. |
Pomalidomide | The serum concentration of Pomalidomide can be increased when it is combined with Capmatinib. |
Ponatinib | The serum concentration of Ponatinib can be increased when it is combined with Capmatinib. |
Posaconazole | The metabolism of Capmatinib can be decreased when combined with Posaconazole. |
Potassium Iodide | The therapeutic efficacy of Potassium Iodide can be decreased when used in combination with Capmatinib. |
Potassium perchlorate | The therapeutic efficacy of Potassium perchlorate can be decreased when used in combination with Capmatinib. |
Pralatrexate | The serum concentration of Pralatrexate can be increased when it is combined with Capmatinib. |
Pralsetinib | The serum concentration of Capmatinib can be decreased when it is combined with Pralsetinib. |
Pramocaine | The risk or severity of methemoglobinemia can be increased when Capmatinib is combined with Pramocaine. |
Prasterone | The serum concentration of Capmatinib can be increased when it is combined with Prasterone. |
Pravastatin | The serum concentration of Pravastatin can be increased when it is combined with Capmatinib. |
Praziquantel | The metabolism of Praziquantel can be decreased when combined with Capmatinib. |
Prazosin | The serum concentration of Prazosin can be increased when it is combined with Capmatinib. |
Prednicarbate | The serum concentration of Capmatinib can be decreased when it is combined with Prednicarbate. |
Prednisolone | The serum concentration of Capmatinib can be decreased when it is combined with Prednisolone. |
Prednisolone phosphate | The serum concentration of Prednisolone phosphate can be increased when it is combined with Capmatinib. |
Prilocaine | The risk or severity of methemoglobinemia can be increased when Capmatinib is combined with Prilocaine. |
Primaquine | The metabolism of Capmatinib can be decreased when combined with Primaquine. |
Primidone | The serum concentration of Capmatinib can be decreased when it is combined with Primidone. |
Probenecid | The serum concentration of Capmatinib can be decreased when it is combined with Probenecid. |
Procainamide | The serum concentration of Procainamide can be increased when it is combined with Capmatinib. |
Procaine | The risk or severity of methemoglobinemia can be increased when Capmatinib is combined with Procaine. |
Progesterone | The serum concentration of Capmatinib can be decreased when it is combined with Progesterone. |
Promazine | The metabolism of Promazine can be decreased when combined with Capmatinib. |
Propafenone | The metabolism of Propafenone can be decreased when combined with Capmatinib. |
Proparacaine | The risk or severity of methemoglobinemia can be increased when Capmatinib is combined with Proparacaine. |
Propoxycaine | The risk or severity of methemoglobinemia can be increased when Capmatinib is combined with Propoxycaine. |
Propranolol | The metabolism of Propranolol can be decreased when combined with Capmatinib. |
Propylthiouracil | The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Capmatinib. |
Protirelin | The therapeutic efficacy of Protirelin can be decreased when used in combination with Capmatinib. |
Prucalopride | The serum concentration of Prucalopride can be increased when it is combined with Capmatinib. |
Quinidine | The serum concentration of Capmatinib can be increased when it is combined with Quinidine. |
Quinine | The serum concentration of Capmatinib can be decreased when it is combined with Quinine. |
Raloxifene | The serum concentration of Raloxifene can be increased when it is combined with Capmatinib. |
Ramelteon | The metabolism of Ramelteon can be decreased when combined with Capmatinib. |
Ranitidine | The metabolism of Ranitidine can be decreased when combined with Capmatinib. |
Ranolazine | The serum concentration of Capmatinib can be increased when it is combined with Ranolazine. |
Rasagiline | The metabolism of Rasagiline can be decreased when combined with Capmatinib. |
Regorafenib | The serum concentration of Regorafenib can be increased when it is combined with Capmatinib. |
Relebactam | The excretion of Relebactam can be decreased when combined with Capmatinib. |
Relugolix | The serum concentration of Relugolix can be increased when it is combined with Capmatinib. |
Remdesivir | The serum concentration of Capmatinib can be increased when it is combined with Remdesivir. |
Reserpine | The serum concentration of Capmatinib can be decreased when it is combined with Reserpine. |
Revefenacin | The serum concentration of Revefenacin can be increased when it is combined with Capmatinib. |
Ribociclib | The metabolism of Capmatinib can be decreased when combined with Ribociclib. |
Rifabutin | The serum concentration of Capmatinib can be decreased when it is combined with Rifabutin. |
Rifampicin | The serum concentration of Capmatinib can be decreased when it is combined with Rifampicin. |
Rifamycin | The serum concentration of Capmatinib can be decreased when it is combined with Rifamycin. |
Rifapentine | The serum concentration of Capmatinib can be decreased when it is combined with Rifapentine. |
Rifaximin | The serum concentration of Capmatinib can be decreased when it is combined with Rifaximin. |
Riluzole | The serum concentration of Riluzole can be increased when it is combined with Capmatinib. |
Rimegepant | The serum concentration of Rimegepant can be increased when it is combined with Capmatinib. |
Riociguat | The serum concentration of Riociguat can be increased when it is combined with Capmatinib. |
Ripretinib | The serum concentration of Ripretinib can be increased when it is combined with Capmatinib. |
Ritonavir | The serum concentration of Capmatinib can be increased when it is combined with Ritonavir. |
Rivaroxaban | The serum concentration of Rivaroxaban can be increased when it is combined with Capmatinib. |
Rofecoxib | The serum concentration of Capmatinib can be decreased when it is combined with Rofecoxib. |
Roflumilast | The serum concentration of Roflumilast can be increased when it is combined with Capmatinib. |
Romidepsin | The serum concentration of Romidepsin can be increased when it is combined with Capmatinib. |
Ropinirole | The risk or severity of adverse effects can be increased when Capmatinib is combined with Ropinirole. |
Ropivacaine | The risk or severity of methemoglobinemia can be increased when Capmatinib is combined with Ropivacaine. |
Rosuvastatin | The serum concentration of Rosuvastatin can be increased when it is combined with Capmatinib. |
Rucaparib | The serum concentration of Rucaparib can be increased when it is combined with Capmatinib. |
Rufinamide | The serum concentration of Capmatinib can be decreased when it is combined with Rufinamide. |
Salmon calcitonin | The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Capmatinib. |
Saquinavir | The metabolism of Capmatinib can be decreased when combined with Saquinavir. |
Sarilumab | The serum concentration of Capmatinib can be decreased when it is combined with Sarilumab. |
Satralizumab | The serum concentration of Capmatinib can be decreased when it is combined with Satralizumab. |
Secobarbital | The serum concentration of Capmatinib can be decreased when it is combined with Secobarbital. |
Selegiline | The metabolism of Selegiline can be decreased when combined with Capmatinib. |
Selexipag | The serum concentration of Selexipag can be increased when it is combined with Capmatinib. |
Selpercatinib | The serum concentration of Capmatinib can be increased when it is combined with Selpercatinib. |
Selumetinib | The serum concentration of Selumetinib can be increased when it is combined with Capmatinib. |
Sildenafil | The serum concentration of Sildenafil can be increased when it is combined with Capmatinib. |
Silodosin | The excretion of Silodosin can be decreased when combined with Capmatinib. |
Siltuximab | The serum concentration of Capmatinib can be decreased when it is combined with Siltuximab. |
Simeprevir | The serum concentration of Simeprevir can be increased when it is combined with Capmatinib. |
Simvastatin | The serum concentration of Simvastatin can be increased when it is combined with Capmatinib. |
Sirolimus | The serum concentration of Sirolimus can be increased when it is combined with Capmatinib. |
Sitagliptin | The serum concentration of Sitagliptin can be increased when it is combined with Capmatinib. |
Sofosbuvir | The serum concentration of Sofosbuvir can be increased when it is combined with Capmatinib. |
Solriamfetol | The excretion of Solriamfetol can be decreased when combined with Capmatinib. |
Somatrogon | The metabolism of Capmatinib can be increased when combined with Somatrogon. |
Sorafenib | The serum concentration of Sorafenib can be increased when it is combined with Capmatinib. |
Sotorasib | The serum concentration of Capmatinib can be decreased when it is combined with Sotorasib. |
St. John’s Wort | The serum concentration of Capmatinib can be decreased when it is combined with St. John’s Wort. |
Stiripentol | The serum concentration of Capmatinib can be increased when it is combined with Stiripentol. |
Sulfasalazine | The serum concentration of Sulfasalazine can be increased when it is combined with Capmatinib. |
Sulfinpyrazone | The serum concentration of Capmatinib can be decreased when it is combined with Sulfinpyrazone. |
Sumatriptan | The serum concentration of Sumatriptan can be increased when it is combined with Capmatinib. |
Tacrine | The metabolism of Tacrine can be decreased when combined with Capmatinib. |
Talazoparib | The serum concentration of Talazoparib can be increased when it is combined with Capmatinib. |
Tamoxifen | The serum concentration of Capmatinib can be decreased when it is combined with Tamoxifen. |
Tasimelteon | The metabolism of Tasimelteon can be decreased when combined with Capmatinib. |
Tazemetostat | The serum concentration of Tazemetostat can be increased when it is combined with Capmatinib. |
Technetium Tc | The serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Capmatinib. |
Tegafur | The serum concentration of Tegafur can be increased when it is combined with Capmatinib. |
Tegaserod | The serum concentration of Tegaserod can be increased when it is combined with Capmatinib. |
Telaprevir | The metabolism of Capmatinib can be decreased when combined with Telaprevir. |
Telithromycin | The metabolism of Capmatinib can be decreased when combined with Telithromycin. |
Telotristat ethyl | The serum concentration of Capmatinib can be decreased when it is combined with Telotristat ethyl. |
Temsirolimus | The serum concentration of Temsirolimus can be increased when it is combined with Capmatinib. |
Teniposide | The serum concentration of Teniposide can be increased when it is combined with Capmatinib. |
Tenofovir alafenamide | The serum concentration of Tenofovir alafenamide can be increased when it is combined with Capmatinib. |
Tenofovir disoproxil | The serum concentration of Tenofovir disoproxil can be increased when it is combined with Capmatinib. |
Tepotinib | The serum concentration of Tepotinib can be increased when it is combined with Capmatinib. |
Terbinafine | The serum concentration of Capmatinib can be decreased when it is combined with Terbinafine. |
Terfenadine | The serum concentration of Capmatinib can be decreased when it is combined with Terfenadine. |
Teriflunomide | The serum concentration of Teriflunomide can be increased when it is combined with Capmatinib. |
Teriparatide | The therapeutic efficacy of Teriparatide can be decreased when used in combination with Capmatinib. |
Testosterone | The serum concentration of Capmatinib can be decreased when it is combined with Testosterone. |
Testosterone cypionate | The serum concentration of Capmatinib can be decreased when it is combined with Testosterone cypionate. |
Testosterone enanthate | The serum concentration of Capmatinib can be decreased when it is combined with Testosterone enanthate. |
Testosterone | The serum concentration of Capmatinib can be decreased when it is combined with Testosterone undecanoate. |
Tetracaine | The risk or severity of methemoglobinemia can be increased when Capmatinib is combined with Tetracaine. |
Tezacaftor | The serum concentration of Tezacaftor can be increased when it is combined with Capmatinib. |
Thalidomide | The serum concentration of Capmatinib can be decreased when it is combined with Thalidomide. |
Theophylline | The serum concentration of Theophylline can be increased when it is combined with Capmatinib. |
Thiabendazole | The metabolism of Thiabendazole can be decreased when combined with Capmatinib. |
Thiopental | The serum concentration of Capmatinib can be decreased when it is combined with Thiopental. |
Thiothixene | The metabolism of Thiothixene can be decreased when combined with Capmatinib. |
Thyroid, porcine | The therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Capmatinib. |
Thyrotropin alfa | The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Capmatinib. |
Ticagrelor | The serum concentration of Ticagrelor can be increased when it is combined with Capmatinib. |
Tipranavir | The metabolism of Capmatinib can be decreased when combined with Tipranavir. |
Tivozanib | The serum concentration of Tivozanib can be increased when it is combined with Capmatinib. |
Tizanidine | The serum concentration of Tizanidine can be increased when it is combined with Capmatinib. |
Tocainide | The metabolism of Tocainide can be decreased when combined with Capmatinib. |
Tocilizumab | The serum concentration of Capmatinib can be decreased when it is combined with Tocilizumab. |
Tolvaptan | The serum concentration of Tolvaptan can be increased when it is combined with Capmatinib. |
Topiramate | The serum concentration of Capmatinib can be decreased when it is combined with Topiramate. |
Topotecan | The serum concentration of Topotecan can be increased when it is combined with Capmatinib. |
Toremifene | The serum concentration of Toremifene can be increased when it is combined with Capmatinib. |
Trametinib | The serum concentration of Capmatinib can be decreased when it is combined with Trametinib. |
Trastuzumab emtansine | The serum concentration of Trastuzumab emtansine can be increased when it is combined with Capmatinib. |
Triamterene | The metabolism of Triamterene can be decreased when combined with Capmatinib. |
Triclabendazole | The metabolism of Triclabendazole can be decreased when combined with Capmatinib. |
Trifluoperazine | The metabolism of Trifluoperazine can be decreased when combined with Capmatinib. |
Trilaciclib | The serum concentration of Trilaciclib can be increased when it is combined with Capmatinib. |
Trimipramine | The serum concentration of Trimipramine can be increased when it is combined with Capmatinib. |
Troglitazone | The serum concentration of Capmatinib can be decreased when it is combined with Troglitazone. |
Troleandomycin | The serum concentration of Capmatinib can be increased when it is combined with Troleandomycin. |
Tucatinib | The serum concentration of Capmatinib can be increased when it is combined with Tucatinib. |
Ubrogepant | The serum concentration of Ubrogepant can be increased when it is combined with Capmatinib. |
Umeclidinium | The serum concentration of Umeclidinium can be increased when it is combined with Capmatinib. |
Ursodeoxycholic acid | The serum concentration of Capmatinib can be decreased when it is combined with Ursodeoxycholic acid. |
Vardenafil | The serum concentration of Vardenafil can be increased when it is combined with Capmatinib. |
Velpatasvir | The serum concentration of Velpatasvir can be increased when it is combined with Capmatinib. |
Vemurafenib | The serum concentration of Capmatinib can be decreased when it is combined with Vemurafenib. |
Venetoclax | The serum concentration of Venetoclax can be increased when it is combined with Capmatinib. |
Verapamil | The serum concentration of Capmatinib can be increased when it is combined with Verapamil. |
Viloxazine | The serum concentration of Capmatinib can be increased when it is combined with Viloxazine. |
Vinblastine | The serum concentration of Capmatinib can be decreased when it is combined with Vinblastine. |
Vincristine | The serum concentration of Vincristine can be increased when it is combined with Capmatinib. |
Vinflunine | The serum concentration of Vinflunine can be increased when it is combined with Capmatinib. |
Voclosporin | The serum concentration of Voclosporin can be increased when it is combined with Capmatinib. |
Voriconazole | The serum concentration of Capmatinib can be increased when it is combined with Voriconazole. |
Voxilaprevir | The serum concentration of Voxilaprevir can be increased when it is combined with Capmatinib. |
Warfarin | The serum concentration of Warfarin can be increased when it is combined with Capmatinib. |
Zafirlukast | The serum concentration of Capmatinib can be increased when it is combined with Zafirlukast. |
Zidovudine | The serum concentration of Zidovudine can be increased when it is combined with Capmatinib. |
Zileuton | The metabolism of Zileuton can be decreased when combined with Capmatinib. |
Zimelidine | The metabolism of Capmatinib can be decreased when combined with Zimelidine. |
Ziprasidone | The metabolism of Capmatinib can be decreased when combined with Ziprasidone. |
Zolmitriptan | The metabolism of Zolmitriptan can be decreased when combined with Capmatinib. |
Zolpidem | The metabolism of Zolpidem can be decreased when combined with Capmatinib. |
Zotepine | The metabolism of Zotepine can be decreased when combined with Capmatinib. |
Pregnancy and Lactation
US FDA pregnancy category: Not assigned.
Pregnancy
Based on findings from animal studies and its mechanism of action, TABRECTA can cause fetal harm when administered to a pregnant woman. There are no available data on TABRECTA use in pregnant women. Oral administration of capmatinib to pregnant rats and rabbits during the period of organogenesis resulted in malformations at maternal exposures less than the human exposure based on AUC at the 400 mg twice daily clinical dose. Advise pregnant women of the potential risk to a fetus. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.
Lactation
There are no data on the presence of capmatinib or its metabolites in either human or animal milk or its effects on the breastfed child or on milk production. Because of the potential for serious adverse reactions in breastfed children, advise women not to breastfeed during treatment with TABRECTA and for 1 week after the last dose.
How should this medicine be used?
Capmatinib comes as a tablet to take by mouth. It is usually taken twice daily with or without food. Take capmatinib at around the same time(s) every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take capmatinib exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.
Swallow the tablets whole; do not split, chew, or crush them.
If you vomit after taking capmatinib, do not take another dose. Continue your regular dosing schedule.
Your doctor may need to temporarily or permanently stop your treatment or decrease your dose of capmatinib during your treatment. This depends on how well the medication works for you and the side effects you experience. Be sure to tell your doctor how you are feeling during your treatment with capmatinib.
Ask your pharmacist or doctor for a copy of the manufacturer’s information for the patient.
What special precautions should I follow?
Before taking capmatinib,
- tell your doctor and pharmacist if you are allergic to capmatinib, any other medications, or any of the ingredients in capmatinib tablets. Ask your pharmacist for a list of the ingredients.
- tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Your doctor may need to change the doses of your medications or monitor you carefully for side effects.
- The following nonprescription or herbal products may interact with capmatinib: St. John’s Wort. Be sure to let your doctor and pharmacist know that you are taking these medications before you start taking capmatinib. Do not start any of these medications while taking capmatinib without discussing with your healthcare provider.
- tell your doctor if you have or have ever had lung disease or breathing problems other than from lung cancer, pancreatitis (swelling of the pancreas), or liver disease.
- tell your doctor if you are pregnant, or plan to become pregnant. You should not become pregnant while you are taking capmatinib. You will need to have a pregnancy test before you start treatment, and you should use birth control to prevent pregnancy during your treatment and for at least 1 week after your final dose. If you are a male with a female partner who may become pregnant, you should use birth control to prevent pregnancy during you treatment and for at least 1 week after your final dose. Capmatinib may harm your unborn baby. If you or your partner become pregnant during your treatment with capmatinib, call your doctor immediately.
- tell your doctor if you are breastfeeding. You should not breastfeed while you are taking capmatinib and for at least 1 week after your final dose.
- plan to avoid unnecessary or prolonged exposure to sunlight and to wear a hat, other protective clothing, sunglasses, and sunscreen.
References